Therapeutische Nanobodies gegen SARS-CoV-2

Monoclonal immunoglobulins are widely successful as therapeutics and have also been effective in treating COVID-19. However, their production in mammalian cells is expensive and cannot be scaled to meet the demand in a global pandemic. Camelid V(H)H antibodies (also called nanobodies), however, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Güttler, Thomas, Dobbelstein, Matthias, Görlich, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Wissenschaft Special
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853039/
https://www.ncbi.nlm.nih.gov/pubmed/35194331
http://dx.doi.org/10.1007/s12268-022-1684-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853039/
https://www.ncbi.nlm.nih.gov/pubmed/35194331
http://dx.doi.org/10.1007/s12268-022-1684-y

Ejemplares similares